KOBIOLABS Venture Capital
3 known investors
Kobiolabs (고바이오랩) develops microbiome-based drugs using its Smartiome platform, which applies AI-driven microbiome multi-omics analysis and a microbial library for drug discovery. The company focuses on immune, metabolic, and brain/neurological diseases, and uses a biofoundry-based microbe drug delivery system (mDDS).
AI & Machine LearningBiotechHealthtech
Investors · 3
Frequently asked questions
- What does KOBIOLABS Venture Capital do?
- Kobiolabs (고바이오랩) develops microbiome-based drugs using its Smartiome platform, which applies AI-driven microbiome multi-omics analysis and a microbial library for drug discovery. The company focuses on immune, metabolic, and brain/neurological diseases, and uses a biofoundry-based microbe drug delivery system (mDDS).
- Who are KOBIOLABS Venture Capital's investors?
- KOBIOLABS Venture Capital's investors include Aju IB Invesment Corporation, Atinum Investment Co. Ltd., IMM Investment Japan.